JTV 161
Alternative Names: JTV-161Latest Information Update: 04 Oct 2023
At a glance
- Originator JT Pharmaceuticals
- Developer Akros Pharma; JT Pharmaceuticals
- Class
- Mechanism of Action Proto oncogene protein c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pulmonary arterial hypertension
Most Recent Events
- 12 Sep 2023 Phase-I clinical trials in Pulmonary arterial hypertension in Unknown location (PO) (Akros Pharma pipeline; September 2023)